Key Takeaways:
Italy's Chiesi Group is set to acquire KalVista Pharmaceuticals Inc. for $1.9 billion, a cash deal at $27.00 per share that has sparked multiple shareholder probes.
"The investigation concerns whether KalVista and its board of directors violated the federal securities laws and/or breached their fiduciary duties by failing to... obtain the best possible price for KalVista shareholders," Halper Sadeh LLC said in a statement.
The offer represents a 36% premium to KalVista’s 30-day volume-weighted average share price as of April 28, 2026, according to a joint statement from the companies. Still, law firms including Ademi LLP and Halper Sadeh have launched investigations into the transaction's fairness and process. The deal, Chiesi's largest to date, is expected to close in the third quarter of 2026, pending regulatory approval and other customary conditions.
The transaction centers on KalVista's lead asset, sebetralstat (brand name EKTERLY®), the first approved oral, on-demand treatment for hereditary angioedema (HAE), a rare genetic disease. For Chiesi, a family-owned firm based in Parma, Italy, the acquisition accelerates its push into rare diseases and is a key part of its goal to reach €6 billion in revenue by 2030. The shareholder investigations question whether investors are being fairly compensated for a drug that booked $49 million in sales in 2025 alone.
Both company boards unanimously approved the transaction. Chiesi is being advised by Lazard and Ropes & Gray LLP, while Centerview Partners LLC is advising KalVista, with legal counsel from Kirkland & Ellis LLP and Fenwick & West LLP.
The deal's closing in the third quarter of 2026 is contingent on regulatory approval and the outcome of these shareholder investigations, which could seek a higher price or other forms of relief. Investors will be watching for any competing bids or updated recommendations from the KalVista board ahead of the planned tender offer.
This article is for informational purposes only and does not constitute investment advice.
